Madrona Ventures Inc.
OTC Bulletin Board : MDRV

September 02, 2009 06:00 ET

Madrona Ventures Inc. Acquires Patents for the Treatment of Obesity

TORONTO, ONTARIO--(Marketwire - Sept. 2, 2009) - A groundbreaking new treatment for obesity is to begin clinical trials in January. Madrona Ventures Inc., an American publicly listed company (OTCBB:MDRV), has acquired the treatment's European patent and the pending American patent application.

The safe and effective treatment is a proprietary patented pharmaceutical medicine-based behaviour programme pioneered by Dr David Sinclair who has already designed a similar treatment program that has shown remarkable results in the treatment of alcoholism.

Madrona Ventures Inc. (soon to be known as Lightlake Therapeutics Inc) is a drug discovery company focusing on developing new and innovative solutions to obesity and eating disorders.

Dr Sinclair, the scientist who discovered this new approach for weight management and obesity, previously patented The Sinclair Method which is already being used by alcohol clinics. Dr Sinclair has now refined this method to provide a precise treatment of eating disorders. The program weakens and removes unhealthy eating habits while simultaneously preserving and reinforcing healthy eating behaviours, exercising, and other calorie-burning activities.

Says Dr Sinclair: "The method is unique because it doesn't view obesity as a single monolithic disease but targets the one in three cases with a specific subtype that can be treated safely and effectively. Finding medicines that cause a loss of weight is easy. Finding one that does so safely is the hard part."

Madrona Ventures Inc. will be starting the phase II double-blind placebo-controlled clinical trial in Finland. The trial will last for six months.

US researchers say obesity related disease costs the US $147billion a year. In Britain, the Department of Health estimates obesity is costing the NHS Pounds Sterling 4.7billion per annum. Both countries estimate that 25% of the population is now obese and these figures are rising. The total market for weight reduction includes obesity drugs but also surgical procedures, diet programs, diet foods, exercise regimes, fitness machines, and spas. The amount spent each year is in excess of a trillion dollars ($1,000,000,000,000), i.e., an order of magnitude higher than the most profitable blockbuster medicine. In the UK alone, the annual cost of obesity to society is estimated at $12 billion (Pounds Sterling 7,500,000,000).

About Dr. David Sinclair

David Sinclair began alcoholism research as an undergraduate at the University of Cincinnati, obtained his Ph.D. in 1972 at the University of Oregon with research showing the link between alcohol drinking and the opiate system, and then immediately joined what is now the renowned unit on prevention and treatment of addictions of Finland's National Institute for Health and Welfare, looking for a better alcoholism treatment. The solution, pharmacological extinction, became apparent after writing the 1981 book, The Rest Principle: A Neurophysiological Theory of Behavior. He subsequently worked on the preclinical studies and clinical trials proving the concept and on practical implementations. His work is featured in Dr. Roy Eskapa's 2008 book, The Cure for Alcoholism.

This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. For those statements, the Company claims the protection of the safe harbor for forward-looking statements provisions contained in the Private Securities Litigation Reform Act of 1995 and any amendments thereto. Such forward-looking statements by definition involve risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. In particular, there is no assurance that production, pricing levels or other factors pertaining to the manufacturing and retail operations will be sustained at the expected rates or levels over time. Discussions of factors, which may affect future results, are contained in the Company's most recent SEC filings.

Contact Information